Skip to main content

IMPORTANT SAFETY INFORMATION 

Myelosuppression

  • Thrombocytopenia, neutropenia, and anemia, including grade 3/4 reactions, have occurred in patients receiving SCEMBLIX

  • Perform complete blood counts every 2 weeks for the first 3 months of treatment and monthly thereafter or as clinically indicated. Monitor patients for signs and symptoms of myelosuppression...

INDICATIONS

SCEMBLIX is indicated for the treatment of adult patients with:

  • Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)

  • Ph+ CML in CP with the T315I mutation...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATIONS

References: 1. Scemblix. Prescribing information. Novartis Pharmaceuticals Corp. 2. Réa D, Mauro M, Boquimpani C, et al. Blood. 2021;138(21):2031-2041. 3. Data on file. CABL001A2301 clinical study report. Novartis Pharmaceuticals Corp; 2022. 4. Soverini S, Gnani A, Colarossi S, et al. Blood. 2009;114(10):2168-2171. 5. Kantarjian HM, Giles FJ, Bhalla KN, et al. Blood. 2011;117(4):1141-1145. 6. O’Brien SG, Guilhot F, Larson RA, et al. N Engl J Med. 2003;348(11):994-1004. 7. Saglio G, Kim D-W, Issaragrisil S, et al. N Engl J Med. 2010;362(24):2251-2259. 8. Kantarjian H, Shah NP, Hochhaus A, et al. N Engl J Med. 2010;362(24):2260-2270. 9. Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. J Clin Oncol. 2018;36(3):231-237. 10. Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Blood. 2011;118(17):4567-4576. 11. Shah NP, Kantarjian HM, Kim D-W, et al. J Clin Oncol. 2008;26(19):3204-3212. 12. Hochhaus A, Réa D, Boquimpani C, et al. Leukemia. 2023;37(3):617-626. 13. Data on file. ABL001 Investigator’s Brochure. Novartis Pharmaceuticals Corp; 2021.